RxDoctor Payments Data

Ariel Sindel, DO

Hematology & Oncology · Akron, OHNPI 1518311505

Payments from drug & device makers

$8,742in general payments, 2019–2025

Across 23 payments — averaging $380.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$8K
  • Incyte Corporation$128
  • AbbVie$109
  • Eisai Inc.$66
  • GSK$32
  • Foundation Medicine, Inc.$24
  • plus $134 from 7 others

What the payments were for

  • Food & beverage$32366%
  • Education$16934%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,742 in reported general payments places this provider in the 50th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$64,297
Medicare patients
256
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide35$717,498
BrukinsaZanubrutinib33$467,948
JakafiRuxolitinib Phosphate29$453,852
ImbruvicaIbrutinib28$450,345
XtandiEnzalutamide19$292,848
TagrissoOsimertinib Mesylate11$187,803
CalquenceAcalabrutinib Maleate11$162,293
Abiraterone Acetate88$154,800
EliquisApixaban42$47,545
Ondansetron Hcl30$1,795
Letrozole62$1,300
Anastrozole33$908
Mirtazapine31$550
Prednisone113$472
Prochlorperazine Maleate15$442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$16$467,94833 claims
Incyte CorporationJakafi$128$453,85229 claims
AstraZenecaTagrisso, Calquence$23$350,09522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →